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BACKGROUND TAVI is now the treatment of choice for patients pre-
senting with severe symptomatic aortic stenosis who are deemed to
be inoperable or of high surgical risk. During the last few years, rapid
improvements have been made to TAVI devices coupled with greater
operator and institutional experience. We sought to determine the
patient and healthcare beneﬁts of contemporary TAVI practice.
METHODS A retrospective analysis was conducted of all patients that
underwent transfemoral TAVI between November 2007 and May 2015
at San Raffaele Scientiﬁc Institute, Milan, Italy. The ﬁrst 150 patients
treated were allocated to the early experience group (EE), and the last
150 patients to the contemporary practice group (CP).
RESULTS Patients were older in the EE group (85.1 vs. 81.5 years,
p<0.001) and of higher risk (10.8 vs. 9.7, p¼0.003) when compared to
the CP group. In the EE group, general anesthetic (22.7% vs. 5.3%,
p<0.001) and surgical cut-down (4% vs. 0%, p<0.001) were more
frequent in comparison to the CP group. Procedure times were also
longer in the EE group (110.4 vs. 74.6 minutes, p¼0.004) as was the
volume of contrast used (208.8 vs. 76.9 milliliters, p<0.001). This
translated into a signiﬁcant reduction in hemoglobin drop (2.4 vs. 1.7
grams/deciliter, p¼0.02) but without a signiﬁcant impact upon plasma
creatinine rise (0.23 vs. 0.18, p¼0.6). As a consequence of these im-
provements patient length of stay was signiﬁcantly shorter in the CP
group (7.2 vs. 9.4 days, p¼0.04).
CONCLUSIONS Advances in TAVI technology, coupled with greater
operator and institutional experience has resulted in signiﬁcant im-
provements in contemporary TAVI practice. In our single high-volume
center experience, this has translated into shorter, less invasive pro-
cedures that have resulted in a signiﬁcantly shorter length of stay.
These improvements have resulted in advantages to both patients(e.g. reduced risk of nosocomial infection) and the healthcare system
with reduced economics costs coupled with beneﬁts of improved
patient ﬂow enabling greater number of patients to be treated.
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BACKGROUND Moderate or severe aortic insufﬁciency (AI) after
transcatheter aortic valve implantation (TAVI) with ﬁrst generation
devices increased acute and long-term mortality. Post-dilation in or-
der to improve procedural outcome increased acute stroke rate. Sec-
ond generation devices are designed to reduce the risk for relevant AI
and offer more control regarding valve positioning. We compared the
repositionable Lotus valve with the balloon-expandable Edwards Sa-
pien 3 valve regarding acute and 30 days outcomes (Clinical Trial
Registration: NCT02162069).
METHODS We evaluated post-procedural AI, need for post-dilation,
rate of permanent pacemaker implantation, and device success ac-
cording to VARC criteria in 221 patients with severe aortic stenosis
undergoing transfemoral TAVI. The repositionable Lotus valve (N¼71)
or the balloon-expandable Edwards Sapien 3 (ES3) valve (N¼150) were
implanted. Baseline parameters did not differ between Lotus and ES3
group with: pulmonary disease 57% vs 57% (p¼0.99), NYHA III or IV in
79% vs 84% (p¼0.30), aortic valve area by echocardiography
0.820.49 cm2 vs 0.800.28 cm2, STS and Euro-Scores. For sizing a
256 multisclice computed tomography (MSCT, Philips Brilliance iCT)
with retrospective ECG triggering was done. Measurements were
performed in systole and area and perimeter derived diameters of the
annulus and left ventricular outﬂow tract were measured. Baseline
MSCT data did not differ with area derived annulus diameter of
24.71.7mm in the Lotus group and 24.72.6mm in the ES3 group
(p¼0.85). Perimeter derived diameter was 25.31.7mm vs
25.42.6mm (p¼0.75). Number of area and perimeter derived di-
ameters of the LVOT were 24.62.2mm vs 24.72.7mm (p¼0.73) and
25.42.3mm vs 25.72.9mm (p¼0.44), respectively. Measurements
were performed with a dedicated software (3mensio 7.0 software, Pie
Medical Imaging, Maastricht, The Netherlands).
RESULTS Post TAVI there was no moderate or severe AI, no need for
post-dilation or use of a second valve in both groups. Contrast amount
was 10738ml for Lotus and 8725ml for ES3 implantation (p<0.05).
There was no moderate or severe AI by echocardiography one day
after TAVI in both groups. There were no death, stroke, annulus
rupture or coronary obstruction. Device success did not differ be-
tween groups and need for pacemaker implantation was signiﬁcantly
higher with Lotus compared with ES3, respectively. Mean regurgita-
tion index was 29.19.2 vs 25.29.7 for Lotus vs ES3 (p¼0.01), mean
aortic gradient by echocardiography 12.04.1mmHg vs
12.64.9mmHg (p¼0.39), respectively.
CONCLUSIONS TAVI with the repositionable Lotus Valve System and
the balloon-expandable Edwards Sapien 3 demonstrated similar acute
and 30 days results. With both second generation TAVI devices there
was no moderate or severe aortic insufﬁciency and no need for post-
dilatation. Device success was similar between groups while need for
permanent pacemaker was signiﬁcantly higher with the Lotus Valve.
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BACKGROUND Recently, a novel balloon-expandable transcatheter
heart valve (THV), the SAPIEN 3 (S 3) has been introduced. While
preliminary data on clinical performance with this device is
